Automated Cell Counter Market Analysis

Automated Cell Counter Market Analysis

Based on product, the automated cell counter industry from the fluorescence image-based cell counter segment is expected to record 5.3% CAGR from 2023 to 2032. The progression can be attributed to the rising number of people suffering from urinary tract infections (UTIs), kidney diseases, and diabetes. Fluorescence image-based cell counting devices provide valuable insights into cellular dynamics, biomarker expression, and disease progression. The growing demand for advanced cell analysis techniques in research, drug discovery, and clinical diagnostics.
 

Automated cell counter market share from the blood cell application segment is expected to reach USD 4.9 billion by 2032. Automated blood cell counting methods are more dependable and effective compared to traditional techniques. The growing adoption of newly developed technologies has increased the need to test the viability of blood cells and detect the kind of cells present in samples. Furthermore, the rising frequency of blood-related illnesses along with the growing need for rapid and dependable diagnostic solutions.
 

North America held over 37.9% of the automated cell counter market share in 2022 and is projected to reach USD 3.8 billion by 2032 driven by the robust presence of well-established healthcare infrastructure and research facilities. The rising prevalence of chronic diseases has spurred the growing need for early disease detection and monitoring, further fueling the demand for automated cell counters.